GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (CHIX:IDIAz) » Definitions » Institutional Ownership

Idorsia (CHIX:IDIAZ) Institutional Ownership : 10.39% (As of May. 03, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Idorsia's institutional ownership is 10.39%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Idorsia's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Idorsia's Float Percentage Of Total Shares Outstanding is 0.00%.


Idorsia Institutional Ownership Historical Data

The historical data trend for Idorsia's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Institutional Ownership Chart

Idorsia Historical Data

The historical data trend for Idorsia can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 14.38 14.27 14.07 12.02 11.52 10.93 10.71 10.71 10.76 10.39

Idorsia Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Idorsia Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines